AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2012
Dec 21, 2012
32418_dirs_2012-12-21_35058c6e-1f2b-47b2-81ec-822643255962.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-12-21
Reporting Person: Brauser Michael (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-12-21 | Employee Stock Options (right to buy) | $1.545 | D | 67500 | Disposed | 2020-05-20 | Common Stock (67500) | Direct |
| 2012-12-21 | Employee Stock Options (right to buy) | $0.945 | A | 41738 | Acquired | 2022-09-15 | Common Stock (41738) | Direct |
Footnotes
F1: These previously awarded options have been terminated in exchange of a new award of options under different terms.
F2: Options vested 1/12th every month for 12 months and have been fully vested as of May 20, 2011.
F3: These 125,000 options are under different terms as filed by the reporting person in a Form 4 on September 27, 2012.
F4: These new options are awarded by terminating the previously awarded options under different terms.
F5: Options vest 1/12th every month for 12 months and will be fully vested as of September 15, 2013.
F6: The total includes 125,000 options under different terms as filed by the reporting perions in a Form 4 on September 27, 2012.